Teleflex Incorporated (TFX) Director Sells $663,075.00 in Stock

Teleflex Incorporated (NYSE:TFX) Director Stuart A. Randle sold 2,500 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $265.23, for a total value of $663,075.00. Following the completion of the sale, the director now owns 7,921 shares of the company’s stock, valued at approximately $2,100,886.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE TFX traded up $1.37 on Friday, reaching $265.88. The company had a trading volume of 285,000 shares, compared to its average volume of 311,126. The company has a market capitalization of $11.84 billion, a PE ratio of 31.65, a P/E/G ratio of 2.08 and a beta of 1.12. The company has a current ratio of 2.26, a quick ratio of 1.51 and a debt-to-equity ratio of 0.83. Teleflex Incorporated has a 52 week low of $227.52 and a 52 week high of $288.78.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, November 1st. The medical technology company reported $2.52 EPS for the quarter, beating analysts’ consensus estimates of $2.41 by $0.11. The business had revenue of $609.70 million during the quarter, compared to the consensus estimate of $609.05 million. Teleflex had a return on equity of 18.04% and a net margin of 2.81%. The firm’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.12 earnings per share. As a group, sell-side analysts predict that Teleflex Incorporated will post 9.91 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Thursday, November 15th will be issued a $0.34 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. Teleflex’s dividend payout ratio (DPR) is currently 16.19%.

Institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC increased its holdings in shares of Teleflex by 200.0% in the second quarter. Parallel Advisors LLC now owns 450 shares of the medical technology company’s stock worth $120,000 after acquiring an additional 300 shares in the last quarter. First Hawaiian Bank bought a new stake in shares of Teleflex in the third quarter worth about $156,000. Qube Research & Technologies Ltd bought a new stake in shares of Teleflex in the second quarter worth about $168,000. First Light Asset Management LLC bought a new stake in shares of Teleflex in the second quarter worth about $210,000. Finally, Dupont Capital Management Corp increased its holdings in shares of Teleflex by 80.5% in the second quarter. Dupont Capital Management Corp now owns 832 shares of the medical technology company’s stock worth $223,000 after acquiring an additional 371 shares in the last quarter. Institutional investors own 89.36% of the company’s stock.

A number of research firms recently commented on TFX. Needham & Company LLC dropped their price objective on Teleflex from $298.00 to $279.00 and set a “buy” rating for the company in a report on Friday, August 3rd. Barclays began coverage on Teleflex in a report on Monday, October 15th. They issued an “equal weight” rating and a $266.00 price objective for the company. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. TheStreet downgraded Teleflex from a “b” rating to a “c+” rating in a report on Friday, August 3rd. Finally, Morgan Stanley dropped their price objective on Teleflex from $310.00 to $295.00 and set an “overweight” rating for the company in a report on Friday, August 3rd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Teleflex presently has an average rating of “Buy” and an average price target of $289.38.

ILLEGAL ACTIVITY NOTICE: “Teleflex Incorporated (TFX) Director Sells $663,075.00 in Stock” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/11/09/teleflex-incorporated-tfx-director-sells-663075-00-in-stock.html.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Further Reading: What are Closed-End Mutual Funds?

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply